Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6187333 | 0.82 | DRD2 (0.38) | DRD2DRD4ALDH1A1MAPTHTR2A | |
| SCHEMBL8527140 | 0.81 | DRD2 (0.39) | DRD2DRD4ALDH1A1MAPTNOTUM | |
| SCHEMBL8529844 | 0.81 | DRD2 (0.39) | DRD2DRD4ALDH1A1MAPTNOTUM | |
| SCHEMBL8528753 | 0.79 | ALDH1A1 (0.45) | DRD2DRD4ALDH1A1MAPTHTR2A | |
| SCHEMBL3237859 | 0.79 | DRD2 (0.38) | DRD2DRD4ALDH1A1MAPTHTR2A | |
| SCHEMBL8529795 | 0.78 | DRD2 (0.52) | DRD2DRD4ALDH1A1MAPTNOTUM | |
| SCHEMBL3242042 | 0.76 | HTR2A (0.40) | DRD2DRD4ALDH1A1MAPTHTR2A | |
| SCHEMBL4138556 | 0.76 | DRD2 (0.46) | DRD2DRD4ALDH1A1MAPTNOTUM | |
| SCHEMBL7079658 | 0.75 | AR (0.48) | DRD2DRD4ALDH1A1MAPTHTR2A | |
| Hydrochloric Acid SCHEMBL7078884 | 0.73 | DRD2 (0.34) | DRD2DRD4ALDH1A1MAPTAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210886-B1 | PYRIMIDYL INDOLINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-09-23 | — | — | EP | disclosed |
| US-8232287-B2 | Pyrimidyl indoline compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20100292259-A1 | PYRIMIDYL INDOLINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-2210886-A1 | PYRIMIDYL INDOLINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-5834494-A | SEROTONIN 5HT2B/2C RECEPTOR ANTAGONISTS; CNS NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; IRRITABLE BOWEL SYNDROME | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-11-10 | — | — | US | disclosed |
| EP-0707581-B1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-02-26 | — | — | EP | disclosed |
| EP-0707581-A1 | INDOLINE DERIVATIVES AS 5HT 2C? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001976-A1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292259-A1 | PYRIMIDYL INDOLINE COMPOUND | GPR119, SLC5A2, SLC5A1 | DRD2 1855/4885DRD4 614/4885ALDH1A1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.